3-furanyl analogs of toxoflavine as kinase inhibitors
The present invention concerns the compounds of formulathe N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein, the use of such compounds as inhibitors of cyclin-dependent serine/threonine kinases (Cdks), as well as kinases and phosphatases involved in cell cycle regulation such as the tyrosine kinases Wee1, Mik1 and Myt1 or the tyrosine dephosphatases such as Cdc25 and Pyp3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating cell proliferative disorders such as atherosclerosis, restenosis and cancer.
Janssen Pharmaceutica N.V.
A A C
A61P A61P C07D
inventional inventional inventional
Alan Richard William Annette Cornelia Peter Jacobus Johannes Chih Yung Eddy Jean Edgard Jean Fernand Armand
Richardson Connors Bakker Buijnsters Ho Freyne LaCrampe